Collegium Pharmaceutical Inc (NASDAQ:COLL)
| 19.90 Delayed Data As of 3:59pm ET |  -0.83 / -4.00%Today’s Change | 17.24 Today|||52-Week Range 26.91 | -0.65% Year-to-Date |
Latest COLL News | Press Releases
| 6 High Earnings Yield Picks That You Shouldn't Miss Out On 8:24am / Zacks.com - Paid Partner Content | COLL vs. ZTS: Which Stock Should Value Investors Buy Now? Sep 20 / Zacks.com - Paid Partner Content |
| Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy Sep 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 20.73 |
| Today’s open | 20.59 |
| Day’s range | 19.73 - 20.67 |
| Volume | 14,255 |
| Average volume (3 months) | 286,902 |
| Market cap | $731.2M |
Data as of 3:59pm ET, 09/28/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -2.68% |
| Earnings growth (next 5 years) | +42.00% |
| Revenue growth (last year) | +4.49% |
| P/E ratio | 7.3 |
| Price/Sales | 2.27 |
| Price/Book | 3.83 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AFMDAffimed NV | -0.17 | -2.73% |
| PETQPetIQ Inc | -0.12 | -0.47% |
| EGRXEagle Pharmaceutical... | +0.06 | +0.11% |
| LXRXLexicon Pharmaceutic... | -0.23 | -4.29% |
Data as of 4:00pm ET, 09/28/2021
Financials
| Next reporting date | November 11, 2021 |
| EPS forecast (this quarter) | $0.96 |
| Annual revenue (last year) | $310.0M |
| Annual profit (last year) | $26.8M |
| Net profit margin | 8.63% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Stoughton, Massachusetts |
Forecasts
